CBER Biologics Effectiveness and Safety (BEST): Initiative Community Engagement and Development Initiative 3
ID: FDA-20-223-SOL-1224066 • Type: Solicitation
• Match:
90%
Opportunity Assistant
Loading
Overview
Response Deadline
Sept. 11, 2020, 2:00 p.m. EDT
Past Due
Posted
Aug. 13, 2020, 4:38 p.m. EDT (updated: Sept. 30, 2020, 12:18 p.m. EDT)
Set Aside
None
Place of Performance
Silver Spring, MD 20993
United States
Source
Current SBA Size Standard
$24 Million
Pricing
Likely Fixed Price
Est. Level of Competition
Average
On 8/13/20 Food and Drug Administration issued Solicitation FDA-20-223-SOL-1224066 for CBER Biologics Effectiveness and Safety (BEST): Initiative Community Engagement and Development Initiative due 9/11/20.
The opportunity was issued full & open with NAICS 611710 and PSC R799.
Primary Contact
Documents
Posted documents for Solicitation FDA-20-223-SOL-1224066
Question & Answer
The AI Q&A Assistant has moved to the bottom right of the page
Opportunity Lifecycle
Procurement notices related to Solicitation FDA-20-223-SOL-1224066
Award Notifications
Agency published notification of awards for Solicitation FDA-20-223-SOL-1224066
IDV Awards
Indefinite delivery vehicles awarded through Solicitation FDA-20-223-SOL-1224066
Incumbent or Similar Awards
Potential Bidders and Partners
Awardees that have won contracts similar to Solicitation FDA-20-223-SOL-1224066
Similar Active Opportunities
Open contract opportunities similar to Solicitation FDA-20-223-SOL-1224066
Experts for CBER Biologics Effectiveness and Safety (BEST): Initiative Community Engagement and Development Initiative
Recommended experts avaliable for hire
Additional Details
Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > FOOD AND DRUG ADMINISTRATION > FDA OFFICE OF ACQ GRANT SVCS
FPDS Organization Code
7524-00223
Source Organization Code
100188033
Last Updated
Sept. 30, 2020
Last Updated By
PI33_DR_IAE_51681
Archive Date
Sept. 26, 2020